Business Valuation Mandate for a Medtech Shareholder Exit
Independent valuation of a Swiss medical device company conducted for a shareholder exit transaction
Description of the mandate: valuation of a Swiss spinal implant medtech player for a shareholder exit
The engagement focused on the determination of the fair economic value of a Swiss company active in the development and commercialisation of innovative medical devices (implants and surgical solutions for the spine). The business valuation was carried out on behalf of a European institutional investor in the context of a shareholder exit, in accordance with international standards and financial governance requirements.
The valuation needed to determine the fair value at a given date, incorporating the volatility of the medtech sector and the sensitivity of clinical data.
Key challenges: valuing a growing medtech in a volatile and sensitive sector
The main challenges of the mandate were:
- identifying the value-creation drivers of a high-growth technology company;
- integrating the volatility of the medtech sector (adoption cycle, regulation, intellectual property);
- assessing the sensitivity of clinical data and its impact on valuation;
- providing an objective discussion basis between shareholders in the context of the institutional exit.
Approach and outcomes: cross-checking DCF, 9-13x EBITDA medtech multiples and patrimonial approach
The valuation deployed several complementary approaches:
- an intrinsic discounted cash flow (DCF) approach with medtech specific risk premium;
- a relative market multiples approach, observed on listed and unlisted comparable companies (9.0x to 13.0x EBITDA depending on innovation level, patent portfolio size and clinical risk profile);
- a complementary patrimonial (substantial) approach to assess the balance sheet structure and R&D investments;
- the practitioners' method, annexed to the valuation report.
The valuation determined a value range consistent with sector references and provided an objective discussion basis between shareholders. The analysis identified the differentiating valuation factors: R&D intensity, regulatory dependence (CE/FDA), innovation pipeline, financing structure. The mandate secured financial governance and strengthened transparency between the parties.
Illustrative example: numerical application to a growing spinal implant medtech
For illustrative purposes only — unrelated to the actual data of the mandate — a spinal implant medtech generating CHF 15M in revenue with EBITDA of CHF 3M (20% margin, growing at 25%) could exhibit an enterprise value range of between CHF 27M and 39M based on 9.0x to 13.0x EBITDA multiples. The medtech premium (vs classic industrial valuation) reflects the depth of the patent portfolio, sustained organic growth and the regulatory barrier to entry.
Summary: 5-week mandate, three cross-checked methods, basis for orderly exit
Business valuation mandate delivered in 5 weeks for a Swiss spinal implant medtech in shareholder exit. Three methods deployed (DCF, 9-13x EBITDA multiples, substantial value, practitioners as annex). Deliverable: value range consistent with sector references, securing financial governance and transparency between shareholders.
Frequently asked questions: medtech multiples, intellectual property, FDA/CE and shareholder exit
What multiples for implant medtechs?
For implant medtechs (orthopaedics, cardiology, neurology), observed EV/EBITDA multiples range between 9.0x and 15.0x, with a significant premium for (i) intellectual property (number/quality of patents), (ii) regulatory maturity (CE/FDA approved), (iii) organic growth > 20%, (iv) pipeline depth. EV/sales multiples stand between 2.0x and 5.0x.
How to value the pipeline and patents of a medtech?
The pipeline and patents are valued (i) implicitly via sector multiples which incorporate future growth, (ii) explicitly via a dedicated intangible asset valuation (probabilistic DCF), (iii) in isolation of the goodwill via a real options approach. The valuation reflects the TRL/MRL of ongoing projects.
What specific risk premium for medtechs?
For medtechs, the specific risk premium integrated into the WACC stands between 2% and 5% above the standard industrial WACC, reflecting (i) regulatory risk (CE/FDA), (ii) clinical risk, (iii) product concentration, (iv) sensitivity to insurer reimbursement. To go further: SCRP and WACC.
How long does a medtech valuation take?
The standard duration is 4 to 7 weeks, depending on portfolio complexity (number of products, patents, commercialisation geographies) and the availability of clinical and regulatory documentation. The mandate described was completed in 5 weeks.
Is the valuation usable for an orderly exit?
Yes. An independent report constitutes (i) a technical arbitration basis between exiting and remaining shareholders, (ii) a fairness opinion annexable to transactional documentation, (iii) a pricing reference vs a potential secondary acquirer, (iv) a defence in case of subsequent challenge.
How to articulate business valuation and intangible valuation?
The articulation rests on a consistency test: the enterprise value must converge with the sum of identified assets (tangible + intangibles including patents, brands, know-how) increased by the residual goodwill. The gap between the business approach and the sum of the parts documents methodological consistency. To go further: PPA.
Similar mandates: other business valuations in healthcare
The transactions shown include those completed by, or with the involvement of, Hectelion team members in current or previous professional roles. They are presented for illustrative purposes only and do not imply exclusive responsibility by Hectelion.
Discover our TRACK RECORD
The transactions presented were carried out by, with the contribution of, or with the participation of members of the Hectelion team in the context of functions performed currently or previously.